Instead, RUNX1 point mutations are associated with stem cell-like, M0 AML with poor prognosis, while expression of CBFβ-SMMHC is associated with a more differentiated, myelomonocytic M4 AML with relatively good prognosis [32-35, 59-61]. The gene discussed is MYH11; the disease is acute myeloid leukemia.